Pfizer’s pneumococcal vaccines have helped to protect children for over 20 years.
But today’s vaccines don’t defend against all bacterial strains. That’s why we are working to develop a vaccine that aims to expand protection against more bacterial strains than our current pneumococcal vaccines.
This study is enrolling healthy toddlers between 12 and 15 months of age who have previously received 3 doses of Pfizer’s currently approved and licensed pneumococcal vaccine (Prevnar 20®).
If you are unsure about your child’s prior vaccination history, or your child is less than 12 months old, you can still take the questionnaire.
To see if this study may be a good fit for you and your family, click “get started” and answer a few questions. There will be other study requirements that the study team will discuss with you, should you choose to take part.
Condition
Pneumococcal disease
Age
12 to 15 months
Vaccination status
Received 3 infant doses of Prevnar 20®
Each clinical trial has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if your child qualifies to enroll in the study.
Answer a 2-minute questionnaire.
A first step as you consider this study is to answer a 2-minute online questionnaire about your child’s health and medical history. If your answers show the study might be a good fit for your child, you may choose to be referred to a study clinic that you select.
Speak with a study representative.
If you’re interested, you will then be asked to provide your contact information for a study representative to contact you and discuss the next steps.
Confirm your child’s eligibility.
Your answers to these questions will only be linked to you if your responses indicate that your child may be eligible to participate in this study and you choose to share your contact information with the study team. Pfizer study team members and our partners will have access to reports containing aggregated data that will not be directly linked back to you or your child. Only the study staff can determine if your child meets the study’s eligibility criteria and is able to enroll in the study.
Children enrolled in this study will be randomly assigned to receive either the study vaccine (called PG4) or a licensed pneumococcal vaccine made by Pfizer (Prevnar 20®).
Your toddler will receive either 1 or 2 doses of PG4 or 1 dose of Prevnar 20®. No children will receive a placebo (vaccine with no active ingredients) in this study.
The study will last for about 6 to 8 months and will require 3 to 4 study visits. There is no cost to participate, and you will be paid for completing study-related activities (amount varies by location).
We know nothing is more important to you as a parent than your child’s wellbeing. Before joining the study, you will be given all the details about participation, including potential benefits and risks. Your child’s health will be carefully monitored throughout the study by the study team.
Number of vaccine doses
Either 1 or 2 doses
Visit schedule
3-4 visits over 6-8 months
Study-related costs
No cost to participate, and you will be paid for your time and effort
Age, genetics, and environmental factors can affect how different children respond to the same vaccine. It’s important to have vaccines that can prevent infection and illness in anyone. To develop better vaccines for everyone, we need families of all backgrounds to get involved in vaccine research.
Taking part in this study may help improve vaccine protection not only for your child, but also other children in the future. Thank you again for considering this clinical trial.
No children will receive a placebo (vaccine with no active ingredients) in this study. Your child will receive either the study vaccine (PG4) or an approved and licensed pneumococcal vaccine made by Pfizer (Prevnar 20®).
There is no cost to participate, and you will be paid for completing study-related activities.
Yes, participation in clinical trials is completely voluntary. Your child’s participation is your choice. You can leave this clinical trial at any time and for any reason.
